Short Summary
Abbott Diabetes Care Inc.'s IPR challenge against DexCom's glucose monitoring patent was instituted by the PTAB. The Board found a reasonable likelihood of success on anticipation and obviousness grounds over prior art reference Gross, despite acknowledging examination complexity. This decision advances Abbott's efforts to invalidate key claims in the medical device space.
Detailed Summary
The Patent Trial and Appeal Board (PTAB) decided to institute an Inter Partes Review (IPR) petition filed by Abbott Diabetes Care Inc. against DexCom, Inc.'s patent 10709364. The petitioner challenged eight claims based on anticipation and obviousness over the prior art reference Gross US 6,275,717 B1. Although the Board noted technical complexities in the file history that complicated the initial examination, it ultimately determined there was a reasonable likelihood of success for Abbott regarding at least one challenged claim. The petitioner successfully argued that Gross discloses specific limitations related to transcutaneous sensing and predictive calibration functions inherent to glucose monitoring technology.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Abbott Diabetes Care Inc. et al. vs DexCom, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Microsoft Corporation et al.vsX1 Discovery, Inc.
The PTAB denied X1 Discovery’s request for an extension to file Director Review briefs in three IPRs against Microsoft, finding no good cause. The Board emphasized that prior case law does not excuse delayed filings.
Apple, Inc.vsTHL Holding Company, LLC
The PTAB issued a Final Written Decision finding claims 11-19 unpatentable over combinations of prior art references. The Petitioner successfully demonstrated that the combination of Kalliola and other references taught or suggested multiple limitations, particularly regarding UWB DoA and location tracking. This decision significantly weakens the patent's validity in the device location/ranging space.
PacifiCorp et al.vsMES, Inc.
PacifiCorp and Birchtech Corp have settled their dispute over U.S. Patent 10,589,225 and jointly moved to terminate the inter partes review involving WEC Energy Group. The motion cites settlement, lack of a merits decision, and public‑policy benefits.
Apple Inc.vsGinko LLC
Apple has filed an IPR petition challenging 12 claims of Ginko’s U.S. Pat. 11,025,573, asserting obviousness over the Robertson and Ahuja prior‑art references. The petition seeks cancellation of the claims to nullify Ginko’s infringement allegations.
PacifiCorp et al.vsMES, Inc.
The PTAB instituted IPR on PacifiCorp's claims against Birchtech Corp. regarding flue gas desulfurization technology, overcoming a time-bar defense raised by the Patent Owner. The Board found Petitioner met the reasonable likelihood standard for institution across multiple grounds of anticipation and obviousness.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.